Nonpharmacologic approaches for the treatment of hyperlipidemia

Cardiology in Review

Volumn 13, Issue 5, 2005, Pages 247-255

  Kermani, Tanaz ^a   Frishman, William H ^b,c  

^a MAYO CLINIC   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Familial hypercholesterolemia; High density lipoprotein infusion; Hyperlipidemia; Low density lipoprotein apheresis; Partial ileal bypass surgery; Vaccination against atherosclerosis

Indexed keywords

ADENOVIRUS VECTOR; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; ATORVASTATIN; AUTOANTIGEN; BILE ACID SEQUESTRANT; CHOLESTEROL ESTER TRANSFER PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETC 216; EZETIMIBE; HEAT SHOCK PROTEIN 60; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; NICOTINIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PARVOVIRUS VECTOR; PRAVASTATIN; PROBUCOL; SIMVASTATIN; STATINE DERIVATIVE; VACCINE;

ABDOMINAL PAIN; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; APHERESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHILL; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIAPHORESIS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EPIDEMIOLOGICAL DATA; FAMILIAL HYPERLIPEMIA; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HEMOPERFUSION; HUMAN; HYPERLIPIDEMIA; ILEUM BYPASS; IMMUNOADSORPTION; ISCHEMIC HEART DISEASE; LIVER TRANSPLANTATION; NAUSEA; NONHUMAN; PORTOCAVAL SHUNT; REVIEW; RIGOR; SAFETY; SIDE EFFECT; UNITED STATES; URTICARIA; VOMITING;

APOLIPOPROTEIN A-I; AUTOANTIGENS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; GENE THERAPY; HUMANS; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; ILEUM; TREATMENT OUTCOME; VACCINATION;

EID: 23944481671     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000137736.74836.dd     Document Type: Review

References (108)

1. The National Heart, Lung and Blood Institute (NHLBI). Facts about coronary heart disease. March 2003. Available at: http://www.nhlbi.nih. gov/health/public/heart/other/chdfacts2.htm. Accessed March 8, 2004.
2. Castelli W, Doyle J, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease: the Cooperative Lipoprotein Phenotyping study. Circulation. 1977;55:767-772.
3. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500.
4. Expert Panel on Detection, Evaluation, arid Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program. JAMA. 2001;285:2486-2497.
5. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
6. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill; 1995:1981-2030.
7. Mabuchi H. Use of LDL-apheresis in the management of familial hypercholesterolemia. Curr Opin Lipidol. 1990;1:43-47.
8. Starzl TE, Bahnson HT, Hardesty RL, et al. Heart-liver transplantation in a patient with familial hypercholesterolemia. Lancet. 1984;1:1382-1383.
9. Deckelbaum RJ, Lees RS, Small DM, et al. Failure of complete bile diversion and oral bile-acid therapy in the treatment of homozygous familial hypercholesterolemia. N Engl J Med. 1977;296:465-470.
10. Starzl TE, Putnam CW, Chase HP, et al. Portacaval shunt in hyperlipoproteinaemia. Lancet. 1973;ii:940-944.
11. Torvik H, Fischer JE, Feldman HA, et al. Effects of intravenous hyperalimentation on plasma lipoproteins in severe familial hypercholesterolaemia. Lancet. 1973;i:601-604.
12. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex-vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med. 1995;1:1148-1154.
13. Buchwald H, Varco RL, Boen JR, et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year post-trial follow-up report from the POSCH: Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med. 1998;158:1253-1261.
14. Bilheimer DW, Goldstein JL, Grundy SM, et al. Reduction in cholesterol and low-density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J Clin Invest. 1975;56:1420-1430.
15. Bilheimer DW. Portacaval shunt and liver transplantation in treatment of familial hypercholesterolemia. Arteriosclerosis. 1989;9:1158-1163.
16. Starzl TE, Putnam CW, Koep LJ. Portacaval shunt and hyperlipidemia. Arch Surg. 1978;113:71-74.
17. De Genne JL, Toutaine R, Maunand B, et al. Forme homozygous cutaneo-tendineuses de xanthomatose hypercholesterolemique dans une observation familiale exemplaire. Essai de plasmapherese a titre de traitaient heroique [in French]. Bull Mem Soc Hop Paris. 1967;118: 1377-1402.
18. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet. 1975;1:1005.
19. Bambauer R, Schiel R, Latza R. Low-density lipoprotein apheresis: an overview. Therapeutic Apheresis and Dialysis. 2003;7:382-390.
20. Vella A, Pineda A, O'Brien T. Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia. Mayo Clin Proc. 2001;76: 1039-1046.
21. Gordon BR, Kelsey SF, Dau PC, et al. Liposorber Study Group. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol. 1998;81:407-411.
22. Lane DM, McConathy WJ, Laughlin LO, et al. Selective removal of plasma low-density lipoprotein with the HELP system: biweekly versus weekly therapy. Atherosclerosis. 1995;114:203-211.
23. Marais D, Naoumova RP, Firth JC, et al. Decreased production of low-density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res. 1997;38:2071-2078.
24. Yamamoto A, Harada-Shiba M, Kawaguchi A, et al. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL apheresis therapy. Atherosclerosis. 2000;153:89-98.
25. Napoli C, Ambrosio G, Scarpato N, et al. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J. 1997;133:585-595.
26. Lihseisen J, Wilhelm M, Hoffman J, et al. Acute effects of LDL-apheresis on cholesterol oxidation products and antioxidants in plasma and lipoproteins of patients with familial hypercholesterolemia. Eur J Med Res. 1994;4:433-441.
27. Donner MG, Parhofer KG, Richter WO, et al. Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis. Metabolism. 1999;48:881-886.
28. Empen K, Otto C, Brodl U, et al. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1 and ICAM-1. J Clin Apheresis. 2002;17:38-43.
29. Thompson GR. LDL apheresis. Atherosclerosis. 2003;167:1-13.
30. Tatami R, Inoue N, Itoh H, et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. LARS Investigators. Atherosclerosis. 1992;95:1-13.
31. Kitabatake A, Sato H, Hori M, et al. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein apheresis: 1 year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group. Clin Ther. 1994;16:416-428.
32. Waidner T, Franzen D, Voelker W, et al. The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study. Clin Invest. 1994;72:858-863.
33. Schuff-Werner P, Gohlke H, Bartmann U. The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur J Clin Invest. 1994;24:724-732.
34. Thompson GR, Maher VM, Matthews S, et al. Familial Hypercholesterolemia Regression Study: a randomized trial of low-density-lipoprotein apheresis. Lancet. 1995;345:811-816.
35. Kroon AA, Aengevaeren WR, van der Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996;93:1826-1835.
36. Richter WO, Donner MG, Hofling B, et al. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism. 1998;47:863-868.
37. Nishimura S, Sekiguchi M, Kano T, et al. Effects of intensive lipid-lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis. 1999;144:409-417.
38. Matsuzaki M, Hiramori K, Imaizumi T, et al. Intravascular ultrasound evaluation of coronary plaque regression by low-density lipoprotein-apheresis in familial hypercholesterolemia. The Low-density lipoprotein Apheresis Coronary Morphology And Reserve Trial (LACMART). J Am Coll Cardiol. 2002;40:220-227.
39. Olbricht CJ, Schaumann D, Fischer D. Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors. Lancet. 1992;340: 908.
40. Koga N, Nagano T, Sato T, et al. Anaphylactoid reactions and bradykinin generation in patients treated with LDL-apheresis and an ACE inhibitor. ASAIO J. 1993;39:M288-291.
41. Sinzinger H, Bednar J, Granegger S, et al. LDL-apheresis and concomitant ACE-inhibitor therapy. Atherosclerosis. 1994;105:115-116.
42. Keller C, Grutzmacher P, Bahr F, et al. LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors [Letter]. Lancet. 1993;341:60-61.
43. Kroon AA, Mol MJ, Stalenhoef AF. ACE inhibitors and LDL-apheresis with dextran sulphate adsorption [Letter]. Lancet. 1992;340:1476.
44. Kannel WB, Neaton JD, Wentworth D, et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT (Multiple Risk Factor Intervention Trial). Am Heart J. 1986;112:825-836.
45. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256:2835-2838.
46. Gordon DJ, Rifkind BM. High density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
47. Stein O, Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis. 1999;144:285-301.
48. Spady DK. Reverse cholesterol transport and atherosclerosis regression. Circulation. 1999;100:576-578.
49. Franceschini G, Maderna P, Sirtori CR. Reverse cholesterol transport: physiology and pharmacology. Atherosclerosis. 1991;88:99-107.
50. Rothblat GH, de la Llera-Moya M, Alger V, et al. Cell cholesterol efflux: integration of old and new observations provides new insight. J Lipid Res. 1999;40:781-796.
51. Navab M, Berliner JA, Watson AD, et al. The yin and yang of oxidation in the development of the fatty streak: a review based on the 1994 Geroge Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol. 1996;16:831-842.
52. Bonnefont-Rousselot D, Therond P, Beaudeux JL, et al. High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis. Clin Chem Lab Med. 1999;37:939-948.
53. Naqvi TZ, Shah PK, Ivey PA, et al. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol. 1999;84:1011-1017.
54. Saku K, Ahmad M, Glas-Greenwalt P, et al. Activation of fibrinolysis by apolipoproteins of high-density lipoproteins in man. Thromb Res. 1985;39:1-8.
55. Cockerill GW, Rye KA, Gamble JR, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987-1994.
56. Barter PJ. Inhibition of endothelial cell adhesion molecule expression by high-density lipoproteins. Clin Exp Pharmacol Physiol. 1997;24: 286-287.
57. Calabresi L, Franceschini G, Sirtori CR, et al. Inhibition of VCAM-1 expression in endothelial cells reconstituted high density lipoproteins. Biochem Biophys Res Commun. 1997;238:61-65.
58. Franceschini G, Sirtori CR, Capurso A, et al. A-I Milano apoprotein: decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66:892-900.
59. Roma P, Gregg RE, Meng MS, et al. In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-I Milano, associated with familial hypoalphalipoproteinemia. J Clin Invest. 1993;38:16307-16314.
60. Badimon JJ, Badimon L, Galvez A, et al. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest. 1989;60:455-461.
61. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234-1241.
62. Miyazaki A, Sakuma S, Morikawa W, et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 1995;15:1882-1888.
63. Shah PK, Nilsson J, Kaul S, et al. Effects of recombinant apolipoprotein A-I (Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 1989;97:780-785.
64. Nissen Se, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA. 2003;290:2292-2300.
65. Rader DJ. High-density lipoproteins as an emerging therapeutic target for atherosclerosis [Editorial]. JAMA. 2003;290:2322-2324.
66. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402.
67. Bisoendial RJ, Hoving GK, Johannes HM, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944-2948.
68. Buchwald H. Lowering of cholesterol absorption and blood levels by ileal exclusion: experimental basis and preliminary clinical report. Circulation. 1964;29:713-720.
69. Buchwald H, Moore RB, Lee GB, et al. Treatment of hypercholesterolemia. Combined dietary, surgical and bile salt binding resin therapy. Arch Surg. 1968;97:275-281.
70. Mol JTM, Stalenhoef AFH, Demacker NM, et al. Low-density lipoprotein catabolism in WHHL rabbits after partial ileal bypass surgery. Biochim Biophys Acta. 1989;1003:167-174.
71. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
72. Starzl TE, Chase HP, Putnam CW, et al. Portacaval shunt in hyperlipoproteinemia. Lancet. 1973;2:940-944.
73. Lopez-Santamaria M, Migliazza L, Gamez M, et al. Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portacaval shunt and ileal bypass. J Pediatr Surg. 2000;35:630-633.
74. Offstad J, Schrumpf E, Geiran O, et al. Plasma exchange and heart-liver transplantation in a patient with homozygous familial hypercholesterolemia. Clin Transplant. 2001;15:432-436.
75. Shrotri M, Fernando BS, Sudhindran S, et al. Long-term outcome of liver transplantation for familial hypercholesterolemia. Transplant Proc. 2003;35:381-382.
76. Sokal EM, Ulla L, Harvengt C, et al. Liver transplantation for familial hypercholesterolemia before the onset of cardiovascular complications. Transplantation. 1993;55:432.
77. Kaji EH, Leiden JM. Gene and stem cell therapies. JAMA. 2001;285: 545-550.
78. Raper SE, Grossman M, Rader DJ, et al. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolaemia. Ann Surg. 1996;223:116-126.
79. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with homozygous familial hypercholesterolaemia. Nat Med. 1994;6:335-341.
80. Lehrmann S. Virus treatment questioned after gene therapy death. Nature. 1999;401:517-518.
81. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286:2244-2245.
82. Oka K, Davis AR, Chan L. Recent advances in liver-directed gene therapy: implications for the treatment of dyslipidemia. Curr Opin Lipidol. 2000;11:179-186.
83. Belalcazar LM, Merched A, Carr B, et al. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation. 2003;107:2726-2732.
84. Shichiri M, Tanaka A, Hirata Y. Intravenous gene therapy for familial hypercholesterolemia using ligand-facilitated transfer of a liposome: LDL receptor gene complex. Gene Ther. 2003;10:827-831.
85. Medin JA, Buttrick PM. Gene transfer in the cardiovascular system. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 2nd ed. New York: McGraw Hill; 2003:777-788.
86. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
87. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1876-1890.
88. Wick G, Schett G, Amberger A, et al. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27-33.
89. Xu Q, Wick G. The role of heat shock proteins in protection and pathophysiology of the arterial wall. Mol Med Today. 1996;2:372-379.
90. Gupta M, Vavasis C, Frishman WH. Heat shock proteins in cardiovascular disease: a new therapeutic target. Cardiol Rev. 2004;12:26-30.
91. Hansson GK. Vaccination against atherosclerosis: science or fiction? Circulation. 2002;106:1599-1601.
92. Palinski W, Rosenfeld ME, Yla-Herttuala S, et al. Low-density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989;86:1372-1376.
93. Palinski W, Ord VA, Plump AS, et al. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titres of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb. 1994;14:605-616.
94. Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low-density lipoprotein and ceriod in chronic periaortitis. Arch Pathol Lab Med. 1990;114:383-387.
95. Witztum JL, Steinbrecher UP, Fisher M, et al. Nonenzymatic glucosylation of homologous low-density lipoprotein and albumin renders them immunogenic in the guinea pig. Proc Natl Acad Sci USA. 1983;80:2757-2761.
96. Palinski W, Miller E, Witztum JL. Immunization of low-density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A. 1995;92:821-825.
97. Ameli S, Hultgardh-Nilsson A, Regnstrom J, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscl Thromb Vasc Biol. 1996;16:1074-1079.
98. Nilsson J, Calara F, Regnstrom J, et al. Immunization with homologous oxidized low-density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J Am Coll Cardiol. 1997;30:1886-1891.
99. George J, Afek A, Gilburd B, et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis. 1998;138:147-152.
100. Zhou X, Caligiuri G, Hamsten A, et al. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:108-114.
101. Feder ME, Hofmann GE. Heat-shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology. Annu Rev Physiol. 1999;61:243-282.
102. Xu Q, Dietrich H, Steiner HJ, et al. Induction of atherosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb. 1992;12:789-799.
103. Faria AMC, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol. 1999;73:153-264.
104. Maron R, Sukhova G, Faria A, et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation. 2002;106:1708-1715.
105. Brewer HB Jr. Increasing HDL cholesterol levels. N Engl J Med. 2004;350:1491-1494.
106. Tall AR. Plasma cholesteryl ester transfer protein and high density lipoproteins: new insights from molecular genetic studies. J Intern Med. 1995;237:5-12.
107. Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160-167.
108. Davidson MH, Maki K, Umporowicz D, et al. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis. 2003;169:113-120.